CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clinicians. 2015;65(2):87–108. doi:10.3322/caac.21262.
   Web of Science ®Google Scholar
• Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–1907. doi:10.1158/1055-9965.epi-10-0437.
   PubMed Web of Science ®Google Scholar
• Wen M, Wang X, Sun Y, Xia J, Fan L, Xing H, Zhang Z, Li X. Detection of EML4-ALK fusion gene and features associated with EGFR mutations in Chinese patients with non-small-cell lung cancer. OncoTargets Ther. 2016:1989. doi:10.2147/ott.s100303.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. Cancer J Clinicians. 2013;63(1):11–30. doi:10.3322/caac.21166.
   Web of Science ®Google Scholar
• Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol. 2013;31(8):1105–1111. doi:10.1200/jco.2012.44.5353.
   PubMed Web of Science ®Google Scholar
• Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015;16(7):E342–E351. doi:10.1016/S1470-2045(15)00077-7.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13(11):772–787. doi:10.1038/nrc3612.
   PubMed Web of Science ®Google Scholar
• Heuckmann JM, Balke-Want H, Malchers F, Peifer M, Sos ML, Koker M, Meder L, Lovly CM, Heukamp LC, Pao W, et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res. 2012;18(17):4682–4690. doi:10.1158/1078-0432.ccr-11-3260.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886.
   PubMed Web of Science ®Google Scholar
• Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–770. doi:10.1634/theoncologist.2015-0497.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009;15(9):3143–3149. doi:10.1158/1078-0432.ccr-08-3248.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara SI, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–U3. doi:10.1038/nature05945.
   PubMed Web of Science ®Google Scholar
• Wong DWS, Leung ELH, Wong SKM, Tin VPC, Sihoe ADL, Cheng LC, Au JSK, Chung LP, Wong MP. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer. 2011;117(12):2709–2718. doi:10.1002/cncr.25843.
   PubMed Web of Science ®Google Scholar
• Togashi Y, Soda M, Sakata S, Sugawara E, Hatano S, Asaka R, Nakajima T, Mano H, Takeuchi K, Lo AWI. KLC1-ALK: A novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. Plos One. 2012;7(2):e31323. doi:10.1371/journal.pone.0031323.
   PubMed Web of Science ®Google Scholar
• Choi YL, Lira ME, Hong M, Kim RN, Choi SJ, Song JY, Pandy K, Mann DL, Stahl JA, Peckham HE, et al. A novel fusion of TPR and ALK in lung adenocarcinoma. J Thoracic Oncol. 2014;9(4):563–566. doi:10.1097/jto.0000000000000093.
   PubMed Web of Science ®Google Scholar
• Fang DD, Zhang B, Gu QY, Lira M, Xu Q, Sun HY, Qian MX, Sheng WQ, Ozeck M, Wang ZX, et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thoracic Oncol. 2014;9(3):285–294. doi:10.1097/jto.0000000000000087.
   PubMed Web of Science ®Google Scholar
• Shan L, Jiang PD, Xu F, Zhang WL, Guo L, Wu J, Zeng YX, Jiao YC, Ying JM. BIRC6-ALK, a novel fusion gene in ALK break-apart FISH-negative lung adenocarcinoma, responds to crizotinib. J Thoracic Oncol. 2015;10(6):E37–E39. doi:10.1097/jto.0000000000000467.
   PubMed Web of Science ®Google Scholar
• Tian Q, Deng WJ, Li ZW. Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient. Eur Respir J. 2017;49(4) doi:10.1183/13993003.02149-2016.
   Web of Science ®Google Scholar
• Ruano-Ravina A, Provencio-Pulla M. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. Transl Cancer Res. 2017; 6:S54–S56. doi:10.21037/tcr.2017.02.26.
   Web of Science ®Google Scholar
• Gadgeel SM. Sequencing of ALK inhibitors in ALK plus non-small cell lung cancer. Curr Treat Options Oncol. 2017;18(6):12. doi:10.1007/s11864-017-0479-8.
   PubMed Web of Science ®Google Scholar
• Diener M, Kopka B, Pohl M, Jaeger K-E, Krauss U. Fusion of a coiled-coil domain facilitates the high-level production of catalytically active enzyme inclusion bodies. ChemCatChem. 2016;8(1):142–152. doi:10.1002/cctc.201501001.
   Web of Science ®Google Scholar
• Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discovery. 2012;2(6):495–502. doi:10.1158/2159-8290.cd-12-0009.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer (vol 371, pg 2167, 2014). N Engl J Med. 2015;373(16):1582. doi:10.1056/NEJMx150034.
   Web of Science ®Google Scholar
• Ou SHI, Ahn JS, De Petris L, Govindan R, Yang JCH, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661-+. doi:10.1200/jco.2015.63.9443.
   Web of Science ®Google Scholar
• Toyokawa G, Seto T. ALK inhibitors: what is the best way to treat patients with ALK(+) non-small-cell lung cancer? Clin Lung Cancer. 2014;15(5):313–319. doi:10.1016/j.cllc.2014.05.001.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11(8):473–481. doi:10.1038/nrclinonc.2014.104.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4(120):120ra17–120ra17. doi:10.1126/scitranslmed.3003316.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482. doi:10.1158/1078-0432.ccr-11-2906.
   PubMed Web of Science ®Google Scholar